Articles with public access mandates - Hikmat Al-AhmadieLearn more
Not available anywhere: 29
Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis
VE Strong, T Kennedy, H Al-Ahmadie, L Tang, J Coleman, Y Fong, ...
Surgery 143 (6), 759-768, 2008
Mandates: US National Institutes of Health
Unusual DNA mismatch repair–deficient tumors in Lynch syndrome: a report of new cases and review of the literature
Y Karamurzin, Z Zeng, ZK Stadler, L Zhang, I Ouansafi, HA Al-Ahmadie, ...
Human pathology 43 (10), 1677-1687, 2012
Mandates: US National Institutes of Health
Preoperative accuracy of diagnostic evaluation of the urachal mass
JJ Meeks, HW Herr, M Bernstein, HA Al-Ahmadie, G Dalbagni
The Journal of urology 189 (4), 1260-1262, 2013
Mandates: US National Institutes of Health
Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer
V Osei-Amponsa, JM Buckwalter, L Shuman, Z Zheng, H Yamashita, ...
Oncogene 39 (6), 1302-1317, 2020
Mandates: US National Institutes of Health
Updates on the genomics of bladder cancer and novel molecular taxonomy
H Al-Ahmadie, GJ Netto
Advances in Anatomic Pathology 27 (1), 36-43, 2020
Mandates: US National Institutes of Health
Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on …
HA Al-Ahmadie, BS Carver, AM Cronin, S Olgac, SK Tickoo, SW Fine, ...
Urology 82 (6), 1341-1347, 2013
Mandates: US National Institutes of Health
Urothelial carcinoma with squamous differentiation—the pathologists׳ perspective
LL Gellert, J Warrick, HA Al-Ahmadie
Urologic Oncology: Seminars and Original Investigations 33 (10), 437-443, 2015
Mandates: US National Institutes of Health
Contribution of bladder cancer pathology assessment in planning clinical trials
CC Guo, HA Al-Ahmadie, TW Flaig, AM Kamat
Urologic Oncology: Seminars and Original Investigations 39 (10), 713-719, 2021
Mandates: US National Institutes of Health
Clinicopathologic features of renomedullary interstitial cell tumor presenting as the main solid renal mass
WM Bazzi, H Huang, H Al-Ahmadie, P Russo
Urology 83 (5), 1104-1106, 2014
Mandates: US National Institutes of Health
Precursors of urinary bladder cancer: molecular alterations and biomarkers
AS Taylor, AM Acosta, HA Al-Ahmadie, R Mehra
Human Pathology 133, 5-21, 2023
Mandates: US National Institutes of Health
MP77-01 TARGETED SEQUENCING OF UPPER TRACT UROTHELIAL CARCINOMA
JP Sfakianos, PH Kim, G Iyer, EK Cha, EC Zabor, AA Hakimi, SN Scott, ...
The Journal of Urology 191 (4S), e911-e911, 2014
Mandates: US National Institutes of Health
LBA-17 Multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma
JA Coleman, NC Wong, DD Sjoberg, N Silva, BH Bochner, G Dalbagni, ...
Journal of Urology 201, e999, 2019
Mandates: US National Institutes of Health
PD36-08 PERIOPERATIVE OUTCOMES OF RADICAL CYSTECTOMY FOLLOWING NEOADJUVANT GEMCITABINE, CISPLATIN AND ATEZOLIZUMAB
A Mouzannar, K Whiting, I Ostrovnaya, A Katims, T Durdin, Z Feuer, ...
Journal of Urology 209 (Supplement 4), e983, 2023
Mandates: US National Institutes of Health
MP63-08 CLINICAL AND GENOMIC RISK FEATURES OF HIGH GRADE T1 NON-MUSCLE INVASIVE BLADDER CANCER
C Chu, J Chen, MDEJ Escano, K Whiting, I Ostrovnaya, S Jiang, W Yip, ...
Journal of Urology 209 (Supplement 4), e874, 2023
Mandates: US National Institutes of Health
PD47-03 CHARACTERIZING THE LANDSCAPE OF ACTIONABLE GENOMIC ALTERATIONS TO IDENTIFY OPPORTUNITIES FOR TARGETED THERAPY TRIALS IN PATIENTS WITH LOCALIZED BLADDER CANCER
N Almassi, E Pietzak, N Schultz, A Walasek, H Al-Ahmadie, MY Teo, ...
Journal of Urology 201, e838, 2019
Mandates: US National Institutes of Health
PD43-06 TUMOR STRATIFICATION OF UPPER TRACT UROTHELIAL CARCINOMA BY GENE EXPRESSION PROFILING AND GENETIC VARIATION
T Clinton, K Kim, W Hu, N Almassi, A Tracey, A Lenis, P Reisz, T Durdin, ...
Journal of Urology 206 (Supplement 3), e732-e733, 2021
Mandates: US National Institutes of Health
MP82-07 TRENDS IN PERIOPERATIVE MANAGEMENT AND OUTCOMES IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL NEPHROURETECTOMY AT MEMORIAL SLOAN KETTERING CANCER …
NC Wong, M Assel, A Tracey, RG Alvim, N Almassi, N Singla, G Chesnut, ...
Journal of Urology 203, e1248, 2020
Mandates: US National Institutes of Health
MP55-17 IS UROTHELIAL CARCINOMA WITH SARCOMATOID DIFFERENTIATION RESPONSIVE TO NEOADJUVANT CHEMOTHERAPY?
N Almassi, E Vertosick, D Sjoberg, E Pietzak, E Cha, T Donahue, ...
Journal of Urology 203, e844-e845, 2020
Mandates: US National Institutes of Health
PD47-02 “ACTIONABLE” GENOMIC ALTERATIONS IN CHEMOTHERAPY RESISTANT MUSCLE-INVASIVE BLADDER CANCER
L Telis, T Clinton, N Almassi, MY Teo, S Funt, T Donahue, N Schultz, ...
Journal of Urology 203, e925-e926, 2020
Mandates: US National Institutes of Health
PD19-10 MANAGEMENT OF TESTICULAR GERM CELL TUMOR WITH SECONDARY SOMATIC MALIGNANCY PRESENT IN THE ORCHIECTOMY
NC Wong, S Dason, LW Dean, TN Clinton, S Isharwal, MTA Donoghue, ...
Journal of Urology 203, e385-e386, 2020
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program